J Med Chem

ISSNs: 1520-4804,

References in J Med Chem:

Search this table:

Title	Authors	Year
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.	Siddiqui MA, Hughes SH, Boyer PL, Mitsuya H, Van QN, George C, Sarafinanos SG, Marquez VE	2004
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark PK, Hughes SH, Janssen PA, Arnold E	2004
Solid-state and solution conformations of the potent HIV inhibitor, 4'-azidothymidine.	Maag H, Nelson JT, Steiner JL, Prisbe EJ	1994
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information.	Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X, Eisenberg EJ, Jin W, Kutty N, Leavitt S, Liclican AC, Liu Q, Liu X, Mak J, Perry JK, Wang M, Watkins WJ, Lansdon EB	2009
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.	Himmel DM, Das K, Clark AD, Hughes SH, Benjahad A, Oumouch S, Guillemont J, Coupa S, Poncelet A, Csoka I, Meyer C, Andries K, Nguyen CH, Grierson DS, Arnold E	2005
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.	Högberg M, Sahlberg C, Engelhardt P, Noréen R, Kangasmetsä J, Johansson NG, Oberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lövgren S, Fridborg K, Bäckbro K	1999
Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.	Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld DR, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek GM, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K	2008
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5 -chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.	Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey GB, Liu M, Miller MD, Moyer G, Munshi V, Perlow-Poehnelt RA, Prasad S, Reid JC, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y	2008
Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.	Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Chan JH, Kleim JP, Stammers DK	2007
Molecular design of cholesterols as inhibitors of DNA polymerase alpha.	Oshige M, Kuramochi K, Ohta K, Ogawa A, Kuriyama H, Sugawara F, Kobayashi S, Sakaguchi K	2004
Synthesis and characterization of N2-(p-n-butylphenyl)-2'-deoxyguanosine and its 5'-triphosphate and their inhibition of HeLa DNA polymerase alpha.	Wright GE, Dudycz LW	1984
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.	Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, Stuart DI	1996
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.	Frenkel YV, Clark AD, Das K, Wang YH, Lewi PJ, Janssen PA, Arnold E	2005
Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines.	Trantolo DJ, Wright GE, Brown NC	1986
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.	Hopkins AL, Ren J, Tanaka H, Baba M, Okamato M, Stuart DI, Stammers DK	1999
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.	Freeman GA, Andrews Iii CW, Hopkins AL, Lowell GS, Schaller LT, Cowan JR, Gonzales SS, Koszalka GW, Hazen RJ, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver KL, Reynolds DJ, Milton J, Ren J, Stuart DI, Stammers DK, Chan JH	2004
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).	Janssen PA, Lewi PJ, Arnold E, Daeyaert FF, De Jonge MR, Heeres J, Koymans L, Vinkers MH, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, De Béthune MP, Pauwels R, Das K, Clark AD, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P	2005
6-Anilinouracil-based inhibitors of Bacillus subtilis DNA polymerase III: antipolymerase and antimicrobial structure-activity relationships based on substitution at uracil N3.	Tarantino PM, Zhi C, Gambino JJ, Wright GE, Brown NC	1999
Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.	Ren J, Esnouf RM, Hopkins AL, Stuart DI, Stammers DK	1999
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen RJ, Freeman A, Ferris RG, Andrews CW, Boone LR, Chan JH, Stammers DK	2008
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.	Shi J, McAtee JJ, Schlueter Wirtz S, Tharnish P, Juodawlkis A, Liotta DC, Schinazi RF	1999
Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability studies of novel 2'-deoxycyclonucleosides, 3,5'-cyclo-dG, and 2,5'-cyclo-dT.	Liang F, Jain N, Hutchens T, Shock DD, Beard WA, Wilson SH, Chiarelli MP, Cho BP	2008
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.	Zhi C, Long ZY, Manikowski A, Comstock J, Xu WC, Brown NC, Tarantino PM, Holm KA, Dix EJ, Wright GE, Barnes MH, Butler MM, Foster KA, LaMarr WA, Bachand B, Bethell R, Cadilhac C, Charron S, Lamothe S, Motorina I, Storer R	2006
Quantitative structure-activity relationships of 6-anilinouracils as inhibitors of Bacillus subtilis DNA polymerase III.	Wright GE, Gambino JJ	1984
Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: design, synthesis, and biological evaluation.	Ali A, Taylor GE, Ellsworth K, Harris G, Painter R, Silver LL, Young K	2003
Isosteres of the DNA polymerase inhibitor aphidicolin as potential antiviral agents against human herpes viruses.	Selwood DL, Challand SR, Champness JN, Gillam J, Hibberd DK, Jandu KS, Lowe D, Pether M, Selway J, Trantor GE	1993
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.	Cullen MD, Ho WC, Bauman JD, Das K, Arnold E, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M	2009
Quantitative structure--activity correlations of rifamycins as inhibitors of viral RNA-directed DNA polymerase and mammalian alpha and beta DNA polymerases.	Wu RS, Wolpert-DeFilippes MK, Quinn FR	1980
Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils.	Wright GE, Brown NC	1980
Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides.	Nomura M, Shuto S, Tanaka M, Sasaki T, Mori S, Shigeta S, Matsuda A	1999
Inhibitors of Bacillus subtilis DNA polymerase III. 6-(arylalkylamino)uracils and 6-anilinouracils.	Brown NC, Gambino J, Wright GE	1977
Inhibitors of Bacillus subtilis DNA polymerase III. Structure-activity relationships of 6-(phenylhydrazino)uracils.	Wright GE, Brown NC	1977
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.	Chan JH, Hong JS, Hunter RN, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews CW, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver KL, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK	2001
Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and Gram-positive bacterial growth.	Zhi C, Long ZY, Gambino J, Xu WC, Brown NC, Barnes MH, Butler MM, LaMarr WA, Wright GE	2003
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.	Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X	2010
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.	Hopkins AL, Ren J, Milton J, Hazen RJ, Chan JH, Stuart DI, Stammers DK	2004

Showing 1 to 36 of 36 entries